Cellply abstract accepted at the AACR 2018 Annual Meeting

Bologna (Italy), 4 February 2018

Cellply will present results of clinical testing activities on Acute Myeloid Leukemia patients at the American Association for Cancer Research (AACR) 2018 Annual Meeting, taking place April 14-18 in Chicago.

Results of the study, conducted in collaboration with haematologists and researchers at the Sant’Orsola-Malpighi Polyclinic in Bologna, show the high accuracy obtained with Cellply’s platform in predicting standard therapy outcome.

Title: Lab-on-a-chip-based in-vitro functional profiling proves to be effective in predicting therapy outcome in AML patients
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 3613
Date/Time: Tuesday Apr 17, 2018 8:00 AM – 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 25
Session Category: Clinical Research
Session Title: Biomarker Discovery 4

Link to abstract

View poster online

Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting

Bologna (Italy), 4 November 2016.

Cellply announced today that the results of a scientific collaboration with hematologists at Seragnoli Institute of Sant’Orsola Polyclinic in Bologna (Italy) working on Acute Myeloid Leukemia (AML), a group led by Prof. Giovanni Martinelli, will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH), on December 3-6 in San Diego, CA, USA. “This is a key milestone for our company as it shows the potential of the Open Microwell technology and the IVD platform under development at Cellply to become an important tool for guiding the identification of the appropriate treatment for each patient or patient set through the analysis of biological information that today remain mostly not exploited for patient stratification”, says Massimo Bocchi, CEO of Cellply. “The preliminary data collected within this scientific activity provided good correlation between our test and the clinical outcome, making Cellply’s platform promising for predicting the haematological response, an endpoint of primary importance not only from a clinical standpoint but also for its use within clinical trials”, added Laura Rocchi, Head of Biology at Cellply. The following abstract was accepted for poster presentation by the American Society of Hematology.

Title: Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 1675
Date/Time: Saturday, December 3, 2016, 5:30 PM-7:30 PM
Location: Hall GH (San Diego Convention Center)
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Link to abstract on Blood Journal